NASDAQ:HCWB HCW Biologics Q1 2026 Earnings Results & Report $1.17 -0.09 (-7.14%) Closing price 04:00 PM EasternExtended Trading$1.16 -0.01 (-0.85%) As of 04:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. HCW Biologics beat analyst earnings expectations and met on revenue in its Q1 2026 results, released May 14, 2026. The company reported EPS of $0.37 versus the -$2.64 consensus estimate, while revenue of $6.54 million matched the $6.54 million estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2026Report DateMay 14, 2026TimeBefore Market OpensConference Call8:00 AM ET HCW Biologics EPS ResultsActual EPS$0.37Consensus EPS -$2.64Beat/MissBeat by +$3.01One Year Ago EPSN/AEPS Beat Rate1 of last 5 quartersHCW Biologics Revenue ResultsActual Revenue$6.54 millionExpected Revenue$6.54 millionBeat/MissMet ExpectationsYoY Revenue GrowthN/AUpcoming EarningsHCW Biologics' Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) HCW Biologics Q1 2026 Earnings FAQ Did HCW Biologics beat earnings estimates for Q1 2026? HCW Biologics (NASDAQ:HCWB) reported earnings of $0.37 per share for Q1 2026, beating the consensus estimate of -$2.64. The report was announced on Thursday, May 14, 2026. What was HCW Biologics' revenue for Q1 2026? HCW Biologics reported revenue of $6.54 million for Q1 2026, against a consensus estimate of $6.54 million. When is HCW Biologics' next earnings date? HCW Biologics' next earnings date is estimated for Thursday, November 12, 2026. MarketBeat tracks confirmed and estimated earnings dates for HCW Biologics on the company's earnings history page. HCW Biologics Earnings HeadlinesHCW Biologics (NASDAQ:HCWB) Stock Rating Lowered by Wall Street ZenOctober 10, 2026 | americanbankingnews.comHCW Biologics Reports FDA Type B Meeting Guidance for HCW11-018b IND Preparation in Solid TumorsOctober 9, 2026 | quiverquant.comQFederal Reserve Reveals Disturbing New Plan To Control Your MoneyA Federal Reserve filing, Docket No. OP-1670, is drawing scrutiny for language that could expand the Fed's visibility into consumer bank transactions. A pilot program is reportedly already underway, with wider rollout at major banks possibly beginning this summer. Martin D. Weiss, PhD, founder of Weiss Ratings, breaks down what the document says and what steps account holders might consider.October 14 at 1:00 AM | Weiss Ratings (Ad)HCW Biologics Maintains Momentum Toward Completion of IND Application for Clinical Study to Evaluate Lead T-Cell Engager in Solid TumorsOctober 9, 2026 | globenewswire.comHCW Biologics Prices $1.5M Private PlacementSeptember 24, 2026 | rttnews.comHCW Biologics Announces Strategic $1.5 Million FinancingSeptember 24, 2026 | tipranks.comSee More HCW Biologics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like HCW Biologics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on HCW Biologics and other key companies, straight to your email. Email Address About HCW BiologicsHCW Biologics (NASDAQ:HCWB) (NASDAQ: HCWB) is a clinical-stage biotechnology company developing immunotherapies for diseases associated with chronic inflammation, including inflammation linked to aging and age-related conditions. The company’s research is focused on modulating the immune system to address “inflammaging,” a persistent, low-grade inflammatory state that may contribute to multiple diseases. HCW Biologics’ product candidates are based on its proprietary immunotherapy platform, which is designed to combine immune-stimulating and inflammation-modulating activities in a single biologic. Its lead candidate, HCW9218, is an investigational fusion protein intended to stimulate immune responses while inhibiting transforming growth factor beta, a signaling protein involved in immune suppression and disease progression. The company has evaluated HCW9218 in clinical research involving cancer and other inflammation-related conditions. Founded in 2018, HCW Biologics is headquartered in the United States and has focused its development activities on advancing biologic therapies through clinical testing. The company’s programs are intended for potential applications in oncology, immune disorders and diseases associated with chronic inflammation, although its candidates remain investigational and have not been established as approved treatments.View HCW Biologics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Citi Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenIREN Limited's AI Pivot Gains Traction—But Can Its Data Centers Deliver?PBF Energy's Stunning Rally Faces a Critical TestA Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Albertsons Is Betting on a Turnaround—But Will It Pay Off?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American Business Upcoming Earnings Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026)U.S. Bancorp (10/15/2026)Prologis (10/15/2026)Taiwan Semiconductor Manufacturing (10/15/2026)Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
